

DR SONALI KOCHHAR,
M.D.
Contact: +91-9810848944
Email: sonalikochar@yahoo.co.in

SECTION A: INDIVIDUAL INFORMATION

A.1. Personal Information

Name	Sonali Kochhar, MD
Post or Position	<ul style="list-style-type: none">• Medical Director, Global Healthcare Consulting• Clinical Associate Professor, Department of Global Health, University of Washington, Seattle
Employer, Research Institution or Affiliation	Global Healthcare Consulting; University of Washington, Seattle

A.2. Short Biography

Dr Sonali Kochhar, MD, Clinical Associate Professor, Department of Global Health, University of Washington, Seattle, and Medical Director, Global Healthcare Consulting has over 23 years of leadership experience for global vaccines and drugs development in the pharmaceutical industry, product development partnerships and consulting. This includes leading Phase I-IV clinical research, safety studies and implementation research conducted in USA, Europe, Africa and Asia in adult, maternal, adolescent, and pediatric populations; vaccines for infectious diseases (COVID-19, HIV/AIDS, tuberculosis, influenza, GBS, RSV, MERS, rift valley fever, lassa, nipah, ebola, zika, chikungunya, pertussis, diarrheal and tropical diseases and polio eradication); maternal immunization (MI); safety, regulatory and ethical strategies for novel vaccines clinical research and implementation (including for epidemics and pregnant women); introduction of new vaccines; increasing immunization coverage and acceptance; vaccine policy recommendations; pandemics and epidemics preparedness and response; translating research into impactful programs by policy, strategy, advocacy, building functional pharmacovigilance (PV) systems, and healthcare systems (including supply chains) strengthening for immunization programs; clinical trial data sharing; and research with vulnerable and at-risk populations (including pregnant women, children, and immunocompromised). Her work has informed global and country specific vaccine policy recommendations. She has been very involved in national, regional and global response efforts for COVID-19 including the development of COVID-19 vaccines, their safety assessment, policy development and implementation.

Dr Kochhar has led vaccine research programs in Kenya, Uganda, Zambia, The Gambia, South Africa, the United States, Belgium, Germany, India, Bangladesh and Nepal. She provides expertise for vaccine research and development and safety (including for viral vectors, nucleic acid (DNA and RNA), inactivated, live-attenuated, protein vaccines and adjuvants).

She has led multi-country clinical development programs, including the development and management of the clinical and regulatory strategies, clinical development plans, target product profiles, protocols, investigators brochures, care and treatment guidelines, safety assessment,

AESI and background rates determination, PV including risk management plans, risk evaluation and mitigation strategies, benefit-risk assessment pre-and post-licensure, and use of innovative clinical trial designs for global vaccine development. She has been responsible for the design, implementation, and evaluation of multi-country vaccine clinical research programs and successfully built and led large international teams for clinical research, registration and post marketing support.

She has co-authored internationally accepted guidance, research standards, protocol templates and case definitions for vaccine clinical research, MI and safety. She is leading the development of an automated template for vaccine benefit-risk assessment. She has led the development of standardized templates for the benefit-risk assessment of vaccines from all platforms, which have been recommended by WHO's Global Advisory Committee on Vaccine Safety (GACVS), and are being widely utilized by vaccine developers. She helped set up and lead the BMGF funded multi-year Global Alignment of Immunization Safety Assessment in Pregnancy (GAIA) network, a critical program for vaccine safety, with partners in over 90 countries. She helped develop 21 novel Maternal and Neonatal Case Definitions for adverse events detection and evaluation, ensuring their applicability in LMICs. The definitions and guidance are being utilized in clinical research, PV, epidemiological studies and implementation research for vaccines and MI globally. She helped develop the "WHO COVID-19 Vaccines Safety Surveillance Manual" which is being used for vaccine pharmacovigilance globally.

For vaccine policy development, she has helped lead the development of the Evidence Considerations for Vaccine Policy (ECVP) framework, to help in early (pre-phase 3 trial design) alignment between regulators, policy makers and the national, regional and global stakeholders on the clinical trial and observational data or evidence needed for policy and program decisions for new vaccine classes, and help mitigate delays in post-licensure vaccine implementation. The ECVP for TB vaccines for adolescents and adults has been developed as the first ECVP.

She is providing support for new vaccines implementation and strengthening vaccine safety activities in LMICs. She is helping set up a Pregnancy Registry for vaccines in a LMIC in Africa and working on a multi-country collaborative COVID-19 vaccine safety research project. She has led immunization programs strengthening by policy and strategy development and healthcare systems strengthening (including evaluation, capacity building, supply chains strengthening, and new technology development and implementation). She has led work on increasing immunization coverage and acceptance in LMICs, and new vaccine introduction, working in close collaboration with the National EPI teams.

Dr Kochhar has helped set up international strategic partnerships and led advocacy for vaccine development with government partners and ministries of health, regulatory bodies (including the FDA, EMA, African and Asian National Regulatory Authorities), ethical committees, scientific organizations, international aid agencies (including BMGF, USAID, Wellcome and MRC), public health authorities, international and bilateral organizations (including WHO, NIH, CDC, World Bank), pharmaceutical companies, key opinion leaders, local communities, patient groups and the media. She has a track-record for launching and coordinating public private vaccine development partnerships to accelerate the development, clinical research, registration, introduction and commercialization of vaccines and drugs of public health

importance for LMICs, including with international pharmaceutical companies, and national government partners.

She serves on several advisory panels including the WHO Strategic Advisory Group of Experts on Immunization (SAGE); Chair of the WHO SAGE Working Group (WG) on COVID-19 vaccines; Gavi's Vaccine investment Strategy (VIS) Steering Committee; Co-Chair of the WHO Evidence Considerations for Vaccine Policy (ECVP) WG; Advisory Board for Bill & Melinda Gates Medical Research Institute for the TB Vaccine Phase 3 trial; WHO Technical Advisory Group on the Development of a Roadmap for Global Introduction of New TB Vaccines; Co-Chair of the WHO Technical Advisory Group on GBS Vaccine Development; WHO Expert Steering Committee on Safety Surveillance in Pregnancy in LMICs; Co-Chair of the WHO COVID-19 Ethics & Governance WG; Co-Chair of the WHO Ethics and Monkeypox WG; Independent Review Panels for Clinical Study Data Requests, and Vivli (Centre for Global Clinical Research Data); International Executive Committees including the International Network of Special Immunization Services (INSIS) Steering Committee; MRC funded Immunizing Pregnant Women and Infants (IMPRINT) network and the co-lead for the challenge on vaccine safety monitoring in LMIC; International Alliance for Biological Standardization, Switzerland's Human Vaccine Committee; and Chair of the Brighton Collaboration Science Board. She is a Research Committee member of the Infectious Diseases Society of America (IDSA); Expert Evaluator for the European Commission; European Science Foundation; Medical Research Council, UK; and Canadian Institutes of Health Research; and a Medical Advisory Panel member of Group B Strep Support, UK. She was an Expert Committee member of the National Academies of Science, Engineering, and Medicine on Clinical Trial Data Sharing; served on the WHO Global Advisory Committee on Vaccine Safety (GACVS) Working Group on COVID-19 Vaccines Safety Preparedness, International Steering Committee of the WHO Consultation on Safety of Immunization in Pregnancy in Mothers and Newborn Children; BMGF's Global Health Clinical Consortium Leadership Group; Expert Working Group of the Wellcome funded PREVENT (Pregnancy Research Ethics for Vaccines, Epidemics, and New Technologies) Project; Core Planning Team of the BMGF funded MI PV programs for LMICs and Harvard University's Multi-Regional Clinical Trial Group.

Kochhar serves as Guest Faculty for International Vaccinology Programs, as a reviewer for journals like Lancet and Nature etc. and has published over 144 publications and reviews (including in the Lancet, Nature, JAMA, Annual Review of Virology), and book chapters on vaccine research, MI, PV and COVID-19. She is a member of academic societies, including the Infectious Diseases Society of America (IDSA), American Academy of Pediatrics and the European Society of Pediatric Infectious Diseases (ESPID).

She has received multiple awards including the Yale World Fellowship for 2011 (Yale University's International Leadership Program); Vaccinology Fellowship Award for significant achievements in Vaccinology from Fondation Mérieux and University of Geneva; Global Leadership Awards from Eli Lilly & Company, Indianapolis, U.S.A; Bharat Jyoti (Light of India) Award for medical achievements and the Serviers Young Investigator Award from Institut de Recherches Internationales, Servier, France.

SECTION B: DISCLOSURES

B.1. Financial Interests
None
B.2 Other Real or Potential Conflicts of Interest
None